US20120114705A1 - Water soluble film for oral administration with instant wettability - Google Patents
Water soluble film for oral administration with instant wettability Download PDFInfo
- Publication number
- US20120114705A1 US20120114705A1 US13/292,590 US201113292590A US2012114705A1 US 20120114705 A1 US20120114705 A1 US 20120114705A1 US 201113292590 A US201113292590 A US 201113292590A US 2012114705 A1 US2012114705 A1 US 2012114705A1
- Authority
- US
- United States
- Prior art keywords
- film according
- film
- water
- group
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- a composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed.
- the carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect.
- the film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.
- Mucoadhesive dosage forms for application to the oral cavity which are designed to deliver therapeutic and/or cosmetic agents to the oral mucosa are known in the art.
- U.S. Pat. No. 5,047,244 describes a mucoadhesive carrier allowing the controlled release of a therapeutic agent via the mucosal tissue comprising an anhydrous but hydratable polymer matrix and amorphous fumed silica.
- An optional water-insoluble film can be added to provide a non-adhering surface.
- WO 91/06270 the same authors disclose a trilaminate film suitable for prolonged delivery of an active ingredient in the oral cavity.
- U.S. Pat. No. 4,876,092 discloses a sheet-shaped adhesive preparation comprising an adhesive layer containing certain water-soluble and water-insoluble polymers and a water-insoluble carrier which can adhere to the oral mucosa thereby releasing an active agent to the oral cavity. All the devices so far cited are not completely water soluble and will stay in the oral cavity even after the therapeutic goal has been achieved leaving the patient with a certain discomfort in the mouth resulting mainly from the support layer which leaves an insoluble residue in the mouth.
- EP 0 200 508 B1 and EP 0 381 194 B1 disclose the use of polyethylene films, polyvinyl acetate, ethylene-vinyl acetate copolymers, metal foils, laminates of cloth or paper and a plastic film, and similar materials as soft film supports, whereby synthetic resins like polyethylene, vinyl acetate homopolymers, and ethylene-vinyl acetate are the preferred materials.
- CA 1 263 312 discloses the use of polyolefines such as polyethylene, polypropylene, polyesters, PVC, and non-woven fabrics as soft support materials.
- Both DE 36 30 603 and EP 0 219 762 disclose the use of swellable polymers such as gelatine or corn starch as film forming agents, which upon application to the oral cavity slowly disintegrate, thereby releasing an active ingredient incorporated in the film.
- swellable polymers such as gelatine or corn starch
- the same polymers can also be used to prepare films which are intended for dental cleansing, as described in EP 0 452 446 B1.
- the present invention discloses methods and compositions that are capable of avoiding an adverse feeling by providing the film which is intended for application to the oral mucosa with instant wettability, while achieving adequate tensile strength in the free film to allow for easy coating, converting, and packaging of a consumer-friendly product.
- the present invention contemplates a rapidly dissolving film which can be adhered to the oral cavity thereby releasing a pharmaceutically or cosmetically active agent, said film comprising water-soluble polymers, one or more polyalcohols, and one or more pharmaceutically or cosmetically active ingredients.
- the formulation may contain a combination of certain plasticizers or surfactants, colorants, sweetening agents, flavors, flavor enhancers, or other excipients commonly used to modify the taste of formulations intended for application to the oral cavity.
- the resulting film is characterized by an instant wettability which causes the film to soften immediately after application to the mucosal tissue thus preventing the patient from experiencing any prolonged adverse feeling in the mouth, and a tensile strength suitable for normal coating, cutting, slitting, and packaging operations.
- the mucoadhesive film of the present invention contains as essential components a water-soluble polymer or a combination of water-soluble polymers, one or more plasticizers or surfactants, one or more polyalcohols, and a pharmaceutically or cosmetically active ingredient.
- the polymers used for the mucoadhesive film include polymers which are hydrophilic and/or water-dispersible.
- Preferred polymers are water-soluble cellulose-derivatives. Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or hydroxypropyl cellulose, either alone, or mixtures thereof, are particularly preferred.
- polymers include polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, natural gums like xanthane gum, tragacantha, guar gum, acacia gum, arabic gum, water-dispersible polyacrylates like polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers.
- concentration of the water-soluble polymer in the final film can vary between 20 and 75% (w/w), preferably between 50 and 75% (w/w).
- the surfactants used for the mucoadhesive film may be one or more nonionic surfactants.
- the first component may be a polyoxyethylene sorbitan fatty acid ester or a ⁇ -hydro- ⁇ -hydroxypoly(oxyethylene) poly(oxypropylene)poly(oxyethylene) block copolymer
- the second component may be a polyoxyethylene alkyl ether or a polyoxyethylene castor oil derivative.
- the HLB value of the polyoxyethylene sorbitan fatty acid ester should be between 10 and 20, whereby a range of 13 to 17 is particularly preferred.
- the ⁇ -hydro- ⁇ -hydroxypoly(oxyethylene)poly(oxypropylene) poly(oxyethylene) block copolymer should contain at least 35 oxypropylene-units, preferably not less than 50 oxypropylene-units.
- the polyoxyethylene alkyl ether should have an HLB value between 10 and 20, whereby an HLB value of not less than 15 is preferred.
- the polyoxyethylene castor oil derivative has to have an HLB value of 14-16.
- the ratio between the first and second component of the binary surfactant mixture should be kept within 1:10 and 1:1, more preferably between 1:5 and 1:3.
- the total concentration of surfactants in the final film depends on the properties of the other ingredients, but usually has to stay between 0.1 and 5% (w/w).
- the polyalcohol is used to achieve the desired level of softness of the film.
- examples of polyalcohols include glycerol, polyethylene glycol, propylene glycol, glycerol monoesters with fatty acids or other pharmaceutically used polyalcohols.
- concentration of the polyalcohol in the dry film usually ranges between 0.1 and 5% (w/w).
- the film is well suited for the delivery of a wide range of pharmaceutically active ingredients via the mucous membranes of a patient, particularly the buccal mucosa.
- Therapeutic agents which exhibit absorption problems due to solubility limitations, degradation in the gastro-intestinal tract, or extensive metabolism, are particularly well suited.
- examples of the therapeutic agents include hypnotics, sedatives, antiepileptics, awakening agents, psychoneurotropic agents, neuromuscular blocking agents, antispasmodic agents, antihistaminics, antiallergics, cardiotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, antitussive expectorants, thyroid hormones, sexual hormones, antidiabetics, antitumor agents, antibiotics and chemotherapeutics, and narcotics.
- the amount of drug to be incorporated into the film depends on the kind of drug and is usually between 0.01 and 20% (w/w), but it can be higher if necessary to achieve the desired effect.
- Cosmetically active agents may include breath freshening compounds like menthol, other flavors or fragrances commonly used for oral hygiene, and/or actives used for dental and/or oral cleansing like quarternary ammonium bases.
- flavors may be enhanced using flavor enhancers like tartaric acid, citric acid, vanillin, or the like.
- Colorants which may optionally be mixed in the film must be safe in terms of toxicity and should be accepted by the Food and Drug Administration for use in cosmetics.
- the mucoadhesive film according to the present invention can be prepared as follows: The polyalcohol, surfactants, plasticizers, and possible other ingredients except the water-soluble or water-dispersible polymer(s) are dissolved in a sufficient amount of a solvent which is compatible with them. Examples of compatible solvents include water, alcohols or mixtures thereof. After a clear solution has been formed, the water-dispersible polymer or mixture of the water-dispersible polymers is slowly added with stirring, and heat if necessary, until a clear and homogeneous solution has been formed, followed by the addition of active ingredients and flavors. The solution is coated onto a suitable carrier material and dried to form a film.
- the carrier material must have a surface tension which allows the polymer solution to spread evenly across the intended coating width without soaking in to form a destructive bond between the two.
- suitable materials include non-siliconized polyethylene terephthalate film, non-siliconized kraft paper, polyethylene-impregnated kraft paper, or non-siliconized polyethylene film.
- the coating of the solution onto the carrier material can be performed using any conventional coating equipment.
- a more preferred coating technique would involve a knife-over-roll coating head.
- the thickness of the resulting film depends on the concentration of solids in the coating solution and on the gap of the coating head and can vary between 5 and 200 ⁇ m. Drying of the film is carried out in a high-temperature air-bath using a drying oven, drying tunnel, vacuum drier, or any other suitable drying equipment, which does not adversely affect the active ingredient(s) or flavor of the film. In order to reliably avoid an adverse feeling in the mouth, a dry film thickness of 70 ⁇ m should not be exceeded.
- the dry film can be cut into pieces of suitable size and shape and packed into a suitable container.
- Coating gap and web speed have to be adjustable to achieve a dry film thickness between 20 and 50 ⁇ m.
- the drying temperature depends on the length of the drying oven and the web speed and has to be adjusted to remove the solvents completely, or almost completely, from the film.
- the resulting film is peeled off the carrier web and cut into pieces of a shape and size suitable for the intended use.
- 3 g sorbitol, 1.5 g Kollidon 30 (supplier: BASF), 5 g glycerol, 5 g propylene glycol, 5 g polyethylene glycol, 4 g polysorbate 80 (Tween 80), 8 g Brij 35, 12 g peppermint flavor, and 0.8 g aspartame are dissolved in a mixture containing 400 g water and 400 g ethanol at 60° C. under stirring.
- 28 g hydroxypropylmethyl cellulose are added slowly under stirring.
- the solution is cooled to room temperature and coated onto a suitable carrier web using the coating and drying conditions as described in the previous example. The dry film is again cut into pieces of suitable size and shape.
- 165.4 g Kollidon 30 are dissolved in a solution of 720 ml water and 2660 ml ethanol at ambient temperature with stirring. 220.5 g hydroxypropylmethyl cellulose is then added at 55-60° C. and stirred vigorously until clear and homogeneous. The mixture is then allowed to cool and added in succession are 78.75 g flavor followed by a mixture of 28.88 g nicotine salicylate and 31.5 g caramel liquid in 120 ml water with stirring. The clear, tan-colored solution is coated an dried under the conditions as described in EXAMPLE 1 and the dry film is cut into pieces of a shape and size suitable for the intended use so as to deliver a nicotine dose between 1-2 mg per piece.
Abstract
A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.
Description
- A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.
- Mucoadhesive dosage forms for application to the oral cavity which are designed to deliver therapeutic and/or cosmetic agents to the oral mucosa are known in the art. U.S. Pat. No. 5,047,244 describes a mucoadhesive carrier allowing the controlled release of a therapeutic agent via the mucosal tissue comprising an anhydrous but hydratable polymer matrix and amorphous fumed silica. An optional water-insoluble film can be added to provide a non-adhering surface. In WO 91/06270, the same authors disclose a trilaminate film suitable for prolonged delivery of an active ingredient in the oral cavity.
- In a similar way, U.S. Pat. No. 4,876,092 discloses a sheet-shaped adhesive preparation comprising an adhesive layer containing certain water-soluble and water-insoluble polymers and a water-insoluble carrier which can adhere to the oral mucosa thereby releasing an active agent to the oral cavity. All the devices so far cited are not completely water soluble and will stay in the oral cavity even after the therapeutic goal has been achieved leaving the patient with a certain discomfort in the mouth resulting mainly from the support layer which leaves an insoluble residue in the mouth.
- A number of attempts have been made to reduce the adverse feeling in the oral cavity caused by the rigidity and inflexibility of the support layer by introducing soft film supports. EP 0 200 508 B1 and EP 0 381 194 B1 disclose the use of polyethylene films, polyvinyl acetate, ethylene-vinyl acetate copolymers, metal foils, laminates of cloth or paper and a plastic film, and similar materials as soft film supports, whereby synthetic resins like polyethylene, vinyl acetate homopolymers, and ethylene-vinyl acetate are the preferred materials. In a similar way, CA 1 263 312 discloses the use of polyolefines such as polyethylene, polypropylene, polyesters, PVC, and non-woven fabrics as soft support materials.
- However, these devices still leave the patient with a considerable amount of residue from the water-insoluble support film thereby still causing a feeling of discomfort. The obvious solution to overcome this problem was to develop mucoadhesive films which completely disintegrate, or even completely dissolve in the saliva. Fuchs and Hilmann (DE 24 49 865.5) prepared homogeneous, water-soluble films intended for buccal administration of hormones. They proposed the use of water-soluble cellulose-derivatives, like hydroxyethyl cellulose, hydroxypropyl cellulose, or methyl hydroxypropyl cellulose, as film forming agents.
- Both DE 36 30 603 and EP 0 219 762 disclose the use of swellable polymers such as gelatine or corn starch as film forming agents, which upon application to the oral cavity slowly disintegrate, thereby releasing an active ingredient incorporated in the film. The same polymers can also be used to prepare films which are intended for dental cleansing, as described in EP 0 452 446 B1.
- These preparations still create an adverse feeling in the mouth which is mainly caused by their initial rigidity and delayed softening. Thus, there has still been a demand for a composition for use in the oral cavity which meets the requirement of providing a pleasant feeling in the mouth.
- The present invention discloses methods and compositions that are capable of avoiding an adverse feeling by providing the film which is intended for application to the oral mucosa with instant wettability, while achieving adequate tensile strength in the free film to allow for easy coating, converting, and packaging of a consumer-friendly product.
- The present invention contemplates a rapidly dissolving film which can be adhered to the oral cavity thereby releasing a pharmaceutically or cosmetically active agent, said film comprising water-soluble polymers, one or more polyalcohols, and one or more pharmaceutically or cosmetically active ingredients. Optionally, the formulation may contain a combination of certain plasticizers or surfactants, colorants, sweetening agents, flavors, flavor enhancers, or other excipients commonly used to modify the taste of formulations intended for application to the oral cavity. The resulting film is characterized by an instant wettability which causes the film to soften immediately after application to the mucosal tissue thus preventing the patient from experiencing any prolonged adverse feeling in the mouth, and a tensile strength suitable for normal coating, cutting, slitting, and packaging operations.
- The mucoadhesive film of the present invention contains as essential components a water-soluble polymer or a combination of water-soluble polymers, one or more plasticizers or surfactants, one or more polyalcohols, and a pharmaceutically or cosmetically active ingredient.
- The polymers used for the mucoadhesive film include polymers which are hydrophilic and/or water-dispersible. Preferred polymers are water-soluble cellulose-derivatives. Hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or hydroxypropyl cellulose, either alone, or mixtures thereof, are particularly preferred. Other optional polymers, without limiting the invention, include polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, natural gums like xanthane gum, tragacantha, guar gum, acacia gum, arabic gum, water-dispersible polyacrylates like polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers. The concentration of the water-soluble polymer in the final film can vary between 20 and 75% (w/w), preferably between 50 and 75% (w/w).
- The surfactants used for the mucoadhesive film may be one or more nonionic surfactants. When a combination of surfactants is used, the first component may be a polyoxyethylene sorbitan fatty acid ester or a α-hydro-ω-hydroxypoly(oxyethylene) poly(oxypropylene)poly(oxyethylene) block copolymer, while the second component may be a polyoxyethylene alkyl ether or a polyoxyethylene castor oil derivative. Preferably, the HLB value of the polyoxyethylene sorbitan fatty acid ester should be between 10 and 20, whereby a range of 13 to 17 is particularly preferred. The α-hydro-ω-hydroxypoly(oxyethylene)poly(oxypropylene) poly(oxyethylene) block copolymer should contain at least 35 oxypropylene-units, preferably not less than 50 oxypropylene-units.
- The polyoxyethylene alkyl ether should have an HLB value between 10 and 20, whereby an HLB value of not less than 15 is preferred. The polyoxyethylene castor oil derivative has to have an HLB value of 14-16.
- In order to achieve the desired instant wettability, the ratio between the first and second component of the binary surfactant mixture should be kept within 1:10 and 1:1, more preferably between 1:5 and 1:3.
- The total concentration of surfactants in the final film depends on the properties of the other ingredients, but usually has to stay between 0.1 and 5% (w/w).
- The polyalcohol is used to achieve the desired level of softness of the film. Examples of polyalcohols include glycerol, polyethylene glycol, propylene glycol, glycerol monoesters with fatty acids or other pharmaceutically used polyalcohols. The concentration of the polyalcohol in the dry film usually ranges between 0.1 and 5% (w/w).
- The film is well suited for the delivery of a wide range of pharmaceutically active ingredients via the mucous membranes of a patient, particularly the buccal mucosa. Therapeutic agents which exhibit absorption problems due to solubility limitations, degradation in the gastro-intestinal tract, or extensive metabolism, are particularly well suited. Without limiting the invention, examples of the therapeutic agents include hypnotics, sedatives, antiepileptics, awakening agents, psychoneurotropic agents, neuromuscular blocking agents, antispasmodic agents, antihistaminics, antiallergics, cardiotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, antitussive expectorants, thyroid hormones, sexual hormones, antidiabetics, antitumor agents, antibiotics and chemotherapeutics, and narcotics.
- The amount of drug to be incorporated into the film depends on the kind of drug and is usually between 0.01 and 20% (w/w), but it can be higher if necessary to achieve the desired effect.
- Cosmetically active agents may include breath freshening compounds like menthol, other flavors or fragrances commonly used for oral hygiene, and/or actives used for dental and/or oral cleansing like quarternary ammonium bases. The effect of flavors may be enhanced using flavor enhancers like tartaric acid, citric acid, vanillin, or the like. Colorants which may optionally be mixed in the film must be safe in terms of toxicity and should be accepted by the Food and Drug Administration for use in cosmetics.
- The mucoadhesive film according to the present invention can be prepared as follows: The polyalcohol, surfactants, plasticizers, and possible other ingredients except the water-soluble or water-dispersible polymer(s) are dissolved in a sufficient amount of a solvent which is compatible with them. Examples of compatible solvents include water, alcohols or mixtures thereof. After a clear solution has been formed, the water-dispersible polymer or mixture of the water-dispersible polymers is slowly added with stirring, and heat if necessary, until a clear and homogeneous solution has been formed, followed by the addition of active ingredients and flavors. The solution is coated onto a suitable carrier material and dried to form a film. The carrier material must have a surface tension which allows the polymer solution to spread evenly across the intended coating width without soaking in to form a destructive bond between the two. Examples of suitable materials include non-siliconized polyethylene terephthalate film, non-siliconized kraft paper, polyethylene-impregnated kraft paper, or non-siliconized polyethylene film.
- The coating of the solution onto the carrier material can be performed using any conventional coating equipment. A more preferred coating technique would involve a knife-over-roll coating head.
- The thickness of the resulting film depends on the concentration of solids in the coating solution and on the gap of the coating head and can vary between 5 and 200 μm. Drying of the film is carried out in a high-temperature air-bath using a drying oven, drying tunnel, vacuum drier, or any other suitable drying equipment, which does not adversely affect the active ingredient(s) or flavor of the film. In order to reliably avoid an adverse feeling in the mouth, a dry film thickness of 70 μm should not be exceeded.
- For better ease of use, the dry film can be cut into pieces of suitable size and shape and packed into a suitable container.
- The invention will now be explained more specifically with reference to the following examples, which are given for illustration of this invention and are not intended to be limiting thereof.
- 15 g of sorbitol, 6 g of glycerol, 0.5 g of polysorbate 80 (Tween 80), 2 g of Brij 35, 25 g of lemon mint flavor, 3 g of aspartame, 15 g of 1-menthol, and 3 g of citrc acid are stirred at 60° C. in a mixture of 250 g water and 250 g ethanol until a clear solution has been formed. To the solution, 30 g of hydroxypropylmethyl cellulose are added slowly under stirring until a clear and homogeneous solution has been formed. The resulting solution is allowed to cool to room temperature and coated onto a suitable carrier material, for example non-siliconized, polyethylene-coated kraft paper using conventional coating/drying equipment. Coating gap and web speed have to be adjustable to achieve a dry film thickness between 20 and 50 μm. The drying temperature depends on the length of the drying oven and the web speed and has to be adjusted to remove the solvents completely, or almost completely, from the film. The resulting film is peeled off the carrier web and cut into pieces of a shape and size suitable for the intended use.
- 3 g sorbitol, 1.5 g Kollidon 30 (supplier: BASF), 5 g glycerol, 5 g propylene glycol, 5 g polyethylene glycol, 4 g polysorbate 80 (Tween 80), 8 g Brij 35, 12 g peppermint flavor, and 0.8 g aspartame are dissolved in a mixture containing 400 g water and 400 g ethanol at 60° C. under stirring. To the clear solution, 28 g hydroxypropylmethyl cellulose are added slowly under stirring. After the polymer is completely dissolved, the solution is cooled to room temperature and coated onto a suitable carrier web using the coating and drying conditions as described in the previous example. The dry film is again cut into pieces of suitable size and shape.
- 15 g sorbitol, 22.5 g glycerol, 2.5 g propylene glycol, 2.5 g Brij 35, 2.5 g polyoxamer 407, 3.5 g Cremophor RH 40, 9 g herb mint flavor, and 0.5 g aspartame are dissolved under stirring at 60° C. in a mixture containing 250 g water and 250 g ethanol. To the clear solution, 75 g hydroxypropyl cellulose are added slowly under continuous stirring. The clear solution is again coated and dried under the conditions as described in EXAMPLE 1 and the dry film is cut into pieces of a shape and size suitable for the intended use.
- 3.6 g Tween 80, 3.6 g glycerol, 39 g menthol, and 171 g Kollidon 30 are dissolved in a solution of 600 ml water and 2800 ml ethanol at ambient temperature with stirring. 247.5 g hydroxypropylmethyl cellulose is then added slowly and portionwise at 50-55° C. and stirred until completely dissolved. The mixture is then allowed to cool and added in succession are 90 g lemon mint flavor followed by a solution/suspension of 27.13 g aspartame, 18 g citric acid, and 0.17 g FD&C yellow #5 in 120 ml water with stirring. The clear solution is coated and dried under the conditions as described in EXAMPLE and the dry film is cut into pieces of a shape and size suitable for the intended use.
- 165.4 g Kollidon 30 are dissolved in a solution of 720 ml water and 2660 ml ethanol at ambient temperature with stirring. 220.5 g hydroxypropylmethyl cellulose is then added at 55-60° C. and stirred vigorously until clear and homogeneous. The mixture is then allowed to cool and added in succession are 78.75 g flavor followed by a mixture of 28.88 g nicotine salicylate and 31.5 g caramel liquid in 120 ml water with stirring. The clear, tan-colored solution is coated an dried under the conditions as described in EXAMPLE 1 and the dry film is cut into pieces of a shape and size suitable for the intended use so as to deliver a nicotine dose between 1-2 mg per piece.
Claims (38)
1-9. (canceled)
10. A film comprising:
i. at least one water-soluble polymer,
ii. at least one polyalcohol, and
iii. at least one pharmaceutically active ingredient.
11. A film according to claim 10 wherein the at least one polyalcohol is selected from the group consisting of glycerol, propylene glycol, glycerol esters with fatty acids and other pharmaceutically used polyalcohols.
12. A film according to claim 11 wherein the concentration of the at least one water-soluble polymer is between 20 and 75% (w/w).
13. A film according to claim 11 wherein the concentration of the at least one polyalcohol is between 0.1 and 5% (w/w).
14. A film according to claim 10 wherein the concentration of at least one pharmaceutically active ingredient is between 0.01 and 20% (w/w).
15. A film according to claim 10 wherein at least one pharmaceutically active ingredient is selected from the group of narcotics.
16. A film according to claim 10 wherein the film has a thickness between 5 and 200 μm.
17. A film according to claim 16 wherein the film has a thickness between 5 and 70 μm.
18. A film according to claim 10 further comprising at least one member of the group consisting of colorants, sweetening agents, flavours, and flavour enhancers.
19. A film according to claim 10 further comprising tartaric acid.
20. A film according to claim 10 further comprising citric acid.
21. A film according to claim 10 further comprising vanillin.
22. A film according to claim 10 wherein
i. a first water-soluble polymer is a water-soluble cellulose derivative and
ii. a second water-soluble polymer is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol and polyethylene glycol.
23. A film according to claim 22 wherein the water-soluble cellulose derivative is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
24. A film according to claim 10 wherein a first water-soluble polymer is hydroxypropylmethyl cellulose and a second water-soluble polymer is polyethylene glycol.
25. A film according to claim 10 wherein the film is capable to release at least one pharmaceutically active ingredient to the oral cavity.
26. A film according to claim 10 wherein the film is rapidly dissolving.
27. A film according to claim 10 wherein the film is mucoadhesive.
28. A film comprising
i. a first water-soluble polymer which is a water-soluble cellulose derivative selected from the group consisting of hydroxypropylmethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose,
ii. a second water-soluble polymer which is selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol and polyethylene glycol, and
iii. at least one pharmaceutically active ingredient.
29. A film according to claim 28 wherein at least one pharmaceutically active ingredient is selected from the group of narcotics.
30. A film according to claim 28 wherein a first water-soluble polymer is hydroxypropylmethyl cellulose and a second water-soluble polymer is polyethylene glycol.
31. A film according to claim 28 wherein the concentration of at least one water-soluble polymer is between 20 and 75% (w/w).
32. A film according to claim 28 wherein the concentration of polyethylene glycol is between 20 and 75% (w/w).
33. A film according to claim 28 further comprising at least one polyalcohol.
34. A film according to claim 28 wherein the concentration of the at least one pharmaceutically active ingredient is between 0.01 and 20% (w/w).
35. A film according to claim 28 wherein the concentration of at least one pharmaceutically active ingredient selected from the group of narcotics is between 0.01 and 20% (w/w).
36. A film according to claim 28 wherein the film has a thickness between 5 and 200 μm.
37. A film according to claim 36 wherein the film has a thickness of between 5 and 70 μm.
38. A film according to claim 28 further comprising at least one member of the group consisting of colorants, sweetening agents, flavours, and flavour enhancers.
39. A film according to claim 28 further comprising tartaric acid.
40. A film according to claim 28 further comprising citric acid.
41. A film according to claim 28 further comprising vanillin.
42. A film according to claim 28 wherein the film is capable to release the at least one pharmaceutically active ingredient to the oral cavity.
43. A film according to claim 28 wherein the film is rapidly dissolving.
44. A film according to claim 28 wherein the film is mucoadhesive.
45. A film comprising:
i. at least one water-soluble hydroxypropylmethyl cellulose,
ii. at least one water-soluble polyethylene glycol in a concentration of between 20 and 75% (w/w),
iii. and at least one pharmaceutically active ingredient selected from the group of narcotics in a concentration of between 0.01 and 20% (w/w).
46. A film according to claim 45 further comprising at least one polyalcohol, at least one colorant, at least one sweetening agent, and citric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/292,590 US20120114705A1 (en) | 1996-11-11 | 2011-11-09 | Water soluble film for oral administration with instant wettability |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19646392.0 | 1996-11-11 | ||
DE19646392A DE19646392A1 (en) | 1996-11-11 | 1996-11-11 | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US08/904,607 US5948430A (en) | 1996-11-11 | 1997-08-01 | Water soluble film for oral administration with instant wettability |
US09/287,181 US6177096B1 (en) | 1996-11-11 | 1999-04-06 | Water soluble film for oral administration with instant wettability |
US09/630,562 US6284264B1 (en) | 1996-11-11 | 2000-08-02 | Water soluble film for oral administration with instant wettability |
US09/927,327 US20010046511A1 (en) | 1996-11-11 | 2001-08-13 | Water soluble film for oral administration with instant wettability |
US10/143,962 US6709671B2 (en) | 1996-11-11 | 2002-05-14 | Water soluble film for oral administration with instant wettability |
US10/771,388 US8865202B2 (en) | 1996-11-11 | 2004-02-05 | Water soluble film for oral administration with instant wettability |
US13/292,590 US20120114705A1 (en) | 1996-11-11 | 2011-11-09 | Water soluble film for oral administration with instant wettability |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/771,388 Division US8865202B2 (en) | 1996-11-11 | 2004-02-05 | Water soluble film for oral administration with instant wettability |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120114705A1 true US20120114705A1 (en) | 2012-05-10 |
Family
ID=7811214
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/904,607 Expired - Lifetime US5948430A (en) | 1996-11-11 | 1997-08-01 | Water soluble film for oral administration with instant wettability |
US09/287,181 Expired - Lifetime US6177096B1 (en) | 1996-11-11 | 1999-04-06 | Water soluble film for oral administration with instant wettability |
US09/630,562 Expired - Lifetime US6284264B1 (en) | 1996-11-11 | 2000-08-02 | Water soluble film for oral administration with instant wettability |
US09/927,327 Abandoned US20010046511A1 (en) | 1996-11-11 | 2001-08-13 | Water soluble film for oral administration with instant wettability |
US10/143,962 Expired - Lifetime US6709671B2 (en) | 1996-11-11 | 2002-05-14 | Water soluble film for oral administration with instant wettability |
US10/161,670 Expired - Lifetime US6592887B2 (en) | 1996-11-11 | 2002-06-05 | Water soluble film for oral administration with instant wettability |
US10/771,388 Expired - Fee Related US8865202B2 (en) | 1996-11-11 | 2004-02-05 | Water soluble film for oral administration with instant wettability |
US13/292,590 Abandoned US20120114705A1 (en) | 1996-11-11 | 2011-11-09 | Water soluble film for oral administration with instant wettability |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/904,607 Expired - Lifetime US5948430A (en) | 1996-11-11 | 1997-08-01 | Water soluble film for oral administration with instant wettability |
US09/287,181 Expired - Lifetime US6177096B1 (en) | 1996-11-11 | 1999-04-06 | Water soluble film for oral administration with instant wettability |
US09/630,562 Expired - Lifetime US6284264B1 (en) | 1996-11-11 | 2000-08-02 | Water soluble film for oral administration with instant wettability |
US09/927,327 Abandoned US20010046511A1 (en) | 1996-11-11 | 2001-08-13 | Water soluble film for oral administration with instant wettability |
US10/143,962 Expired - Lifetime US6709671B2 (en) | 1996-11-11 | 2002-05-14 | Water soluble film for oral administration with instant wettability |
US10/161,670 Expired - Lifetime US6592887B2 (en) | 1996-11-11 | 2002-06-05 | Water soluble film for oral administration with instant wettability |
US10/771,388 Expired - Fee Related US8865202B2 (en) | 1996-11-11 | 2004-02-05 | Water soluble film for oral administration with instant wettability |
Country Status (26)
Country | Link |
---|---|
US (8) | US5948430A (en) |
EP (2) | EP1362584B1 (en) |
JP (3) | JP4063331B2 (en) |
KR (2) | KR100569847B1 (en) |
AT (2) | ATE247954T1 (en) |
AU (1) | AU739698B2 (en) |
CA (1) | CA2265651C (en) |
CZ (1) | CZ297354B6 (en) |
DE (4) | DE19646392A1 (en) |
DK (2) | DK1362584T3 (en) |
ES (2) | ES2322699T3 (en) |
HK (1) | HK1035316A1 (en) |
HU (2) | HU228464B1 (en) |
ID (1) | ID22526A (en) |
IL (2) | IL129819A0 (en) |
MY (1) | MY125548A (en) |
NO (2) | NO325073B1 (en) |
NZ (1) | NZ335063A (en) |
PL (1) | PL190376B1 (en) |
PT (2) | PT936905E (en) |
SI (1) | SI0936905T1 (en) |
SK (2) | SK285999B6 (en) |
TR (1) | TR199901633T2 (en) |
TW (2) | TWI250029B (en) |
WO (1) | WO1998020862A1 (en) |
ZA (1) | ZA9710093B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019121660A1 (en) * | 2017-12-20 | 2019-06-27 | Firmenich Sa | Oral care compositions |
US11129799B2 (en) | 2011-04-12 | 2021-09-28 | Aquestive Therapeutics, Inc. | Dual lane coating |
US11723863B2 (en) | 2018-06-22 | 2023-08-15 | Church & Dwight Co., Inc. | Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom |
Families Citing this family (388)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636001A1 (en) * | 1996-09-05 | 1998-03-12 | Hoechst Ag | Polymer mixtures containing sulfoxide groups |
US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
DE19646392A1 (en) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
DE19832169A1 (en) * | 1998-07-17 | 2000-01-27 | Jenapharm Gmbh | Treating or preventing oral atrophic symptoms, e.g. marginal periodontal disease, by local administration of estrogen such as estriol |
US6358060B2 (en) * | 1998-09-03 | 2002-03-19 | Jsr Llc | Two-stage transmucosal medicine delivery system for symptom relief |
US20020098264A1 (en) * | 1998-11-27 | 2002-07-25 | Cherukuri Subraman R. | Medicated chewing gum delivery system for nicotine |
US20030206942A1 (en) * | 1998-09-25 | 2003-11-06 | Neema Kulkarni | Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent |
US20030211136A1 (en) * | 1998-09-25 | 2003-11-13 | Neema Kulkarni | Fast dissolving orally consumable films containing a sweetener |
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
CN1161107C (en) * | 1998-11-27 | 2004-08-11 | 高田宽治 | Oral formulation for gastrointestinal drug delivery |
DE19856101A1 (en) * | 1998-12-04 | 2000-06-08 | Labtec Gmbh | Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio |
CA2356533C (en) | 1998-12-23 | 2010-07-13 | Mount Sinai School Of Medicine | Inhibitors of the bitter taste response |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
IL144755A0 (en) † | 1999-02-08 | 2002-06-30 | Alza Corp | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
DE19911262C2 (en) * | 1999-03-13 | 2003-04-10 | Scs Skin Care Systems Gmbh | Device for dispensing cosmetic active ingredients |
US6231957B1 (en) | 1999-05-06 | 2001-05-15 | Horst G. Zerbe | Rapidly disintegrating flavor wafer for flavor enrichment |
PL200936B1 (en) | 1999-07-02 | 2009-02-27 | Procter & Gamble | Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
US7314716B2 (en) | 1999-11-19 | 2008-01-01 | Mount Sinai School Of Medicine | Gustducin γ subunit materials and methods |
DE10001096A1 (en) * | 2000-01-13 | 2001-07-26 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for prolonged release of drugs, e.g. steroid hormones, including reservoir providing slow release of perfume to improve patient compliance |
US6387356B1 (en) | 2000-01-27 | 2002-05-14 | Colgate-Palmolive Company | Cosmetic composition |
US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
DE10032456A1 (en) * | 2000-07-04 | 2002-01-31 | Lohmann Therapie Syst Lts | Rapidly disintegrating dosage form for the release of active substances in the mouth or in the body cavities |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
DE10034491A1 (en) * | 2000-07-15 | 2002-01-24 | Scs Skin Care Systems Gmbh | Foil dermatics |
DE10050267A1 (en) * | 2000-10-09 | 2001-12-06 | Karen Croissant | Dental and/or oral cleaning agent, such as toothpaste, tooth gel, tooth powder, medicinal chewing gum, mouthwash, mouth powder, mouth pill or toothpick, comprises psychopharmaceutical |
US20020131990A1 (en) * | 2000-11-30 | 2002-09-19 | Barkalow David G. | Pullulan free edible film compositions and methods of making the same |
US20060062864A1 (en) * | 2000-12-28 | 2006-03-23 | Mccleary Edward L | Weight loss composition and method |
US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
EP1370206A4 (en) * | 2001-01-09 | 2006-04-05 | Lavipharm Lab Inc | Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
DE10107659B4 (en) * | 2001-02-19 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Mucoadhesive disintegratable drug preparation for drug administration in veterinary and human medicine |
US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
US20030068376A1 (en) * | 2001-04-20 | 2003-04-10 | Lavipharm Laboratories Inc. | Intraoral delivery of nicotine for smoking cessation |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
EP1390084B1 (en) | 2001-05-01 | 2011-03-23 | A.V. Topchiev Institute of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
EP1390085B1 (en) | 2001-05-01 | 2009-08-05 | A.V. Topchiev Institute of Petrochemical Synthesis | Hydrogel compositions |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US6660292B2 (en) * | 2001-06-19 | 2003-12-09 | Hf Flavoring Technology Llp | Rapidly disintegrating flavored film for precooked foods |
US6656493B2 (en) * | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
JP2005508888A (en) * | 2001-08-14 | 2005-04-07 | バイオティ セラピーズ コーポレイション | How to treat alcoholism or alcoholism |
US6419903B1 (en) * | 2001-08-20 | 2002-07-16 | Colgate Palmolive Company | Breath freshening film |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
US20100021526A1 (en) * | 2001-10-12 | 2010-01-28 | Monosol Rx, Llc | Ph modulated films for delivery of actives |
US20060039958A1 (en) * | 2003-05-28 | 2006-02-23 | Monosolrx, Llc. | Multi-layer films having uniform content |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
ES2735512T3 (en) | 2001-10-12 | 2019-12-19 | Aquestive Therapeutics Inc | Thin film with uniform non-self-aggregating heterogeneity, process for its production and drug delivery systems made from it |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7357891B2 (en) * | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20070154527A1 (en) * | 2001-10-12 | 2007-07-05 | Monosoirx, Llc | Topical film compositions for delivery of actives |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US7666337B2 (en) * | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US7910641B2 (en) * | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
US7425292B2 (en) * | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
US20050089548A1 (en) * | 2001-11-16 | 2005-04-28 | Virgalitto Margaret T. | Edible film |
US20030099691A1 (en) * | 2001-11-16 | 2003-05-29 | Susan Lydzinski | Films containing starch |
KR100843001B1 (en) * | 2002-01-16 | 2008-07-01 | 동화약품공업주식회사 | Oral Mucoadhesive Film |
WO2003059542A1 (en) | 2002-01-17 | 2003-07-24 | Lts Lohmann Therapie-Systeme Ag | Method for neutralizing or recycling carrier materials for film-like coatings |
US20040247746A1 (en) * | 2002-02-11 | 2004-12-09 | Edizone, Lc | Delivery units of thick orally soluble polymer |
US20030224090A1 (en) * | 2002-02-11 | 2003-12-04 | Edizone, Lc | Snacks of orally soluble edible films |
US20040247744A1 (en) * | 2002-02-11 | 2004-12-09 | Edizone, Lc | Vitamin-containing orally soluble films |
US20050003048A1 (en) * | 2002-02-11 | 2005-01-06 | Edizone, Lc | Electrolyte-containing orally soluble films |
US20040247649A1 (en) * | 2002-02-11 | 2004-12-09 | Edizone, Lc | Medicine-containing orally soluble films |
US20050100640A1 (en) * | 2002-02-11 | 2005-05-12 | Pearce Tony M. | Microcapsule edibles |
CA2476250C (en) * | 2002-02-13 | 2010-08-03 | Michael K. Weibel | Drug dose-form and method of manufacture |
KR20030075213A (en) * | 2002-03-16 | 2003-09-26 | (주)케비젠 | Watersoluble films comprising anti-cancer medicines and their preparation |
US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US20030194420A1 (en) * | 2002-04-11 | 2003-10-16 | Richard Holl | Process for loading a drug delivery device |
CN1655771A (en) * | 2002-05-24 | 2005-08-17 | 艾克发照像有限责任公司 | At least partially degradable films containing an active ingredient and method for the production thereof |
DE10224607B4 (en) * | 2002-06-04 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Film-form, disintegratable preparations for drug release and process for their preparation |
US6937455B2 (en) * | 2002-07-03 | 2005-08-30 | Kronos Advanced Technologies, Inc. | Spark management method and device |
RU2338549C2 (en) * | 2002-06-25 | 2008-11-20 | Вм. Ригли Дж. Компани | Product with extract of magnolia bark, freshening breath and disinfecting oral cavity |
US7347985B2 (en) * | 2002-06-25 | 2008-03-25 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract |
US7632525B2 (en) * | 2002-06-25 | 2009-12-15 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents |
US7595065B2 (en) * | 2002-06-25 | 2009-09-29 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing products with synergistic combinations of magnolia bark extract and essential oils |
US7150780B2 (en) * | 2004-01-08 | 2006-12-19 | Kronos Advanced Technology, Inc. | Electrostatic air cleaning device |
US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
CA2505796C (en) * | 2002-07-22 | 2012-01-03 | Monosolrx Llc | Packaging and dispensing of rapid dissolve dosage form |
US7241411B2 (en) * | 2002-08-23 | 2007-07-10 | Acupac Packaging, Inc. | Thin film strips |
US6824829B2 (en) * | 2002-08-23 | 2004-11-30 | Acupac Packaging, Inc. | Process for manufacturing thin film strips |
EP1534252B1 (en) * | 2002-08-27 | 2010-06-30 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product using cardamom oil |
US20040043134A1 (en) * | 2002-08-27 | 2004-03-04 | Corriveau Christine Leclair | Rolled edible thin film products and methods of making same |
AU2003260091A1 (en) * | 2002-08-27 | 2004-03-19 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product using carvacrol |
US20040120991A1 (en) * | 2002-09-07 | 2004-06-24 | Mars Incorporated | Edible films having distinct regions |
US20050019277A1 (en) * | 2002-09-11 | 2005-01-27 | The Procter & Gamble Company | Tooth whitening products |
US8524200B2 (en) | 2002-09-11 | 2013-09-03 | The Procter & Gamble Company | Tooth whitening products |
US6916463B2 (en) * | 2002-09-24 | 2005-07-12 | The Procter & Gamble Company | Oral products having an aesthetic layer |
US6800295B2 (en) * | 2002-10-09 | 2004-10-05 | The Dial Corporation | Water soluble sheet composition |
FI20022007A0 (en) * | 2002-11-08 | 2002-11-08 | Juvantia Pharma Ltd Oy | Oromucosal preparation and method of preparation thereof |
GB0226076D0 (en) * | 2002-11-08 | 2002-12-18 | Rp Scherer Technologies Inc | Improved formulations containing substituted imidazole derivatives |
DE10252726B4 (en) * | 2002-11-13 | 2008-05-08 | Lts Lohmann Therapie-Systeme Ag | Multilayer transmucosal therapeutic system |
AU2003295577A1 (en) * | 2002-11-14 | 2004-06-15 | Zengen, Inc. | Edible film for relief of cough or symptoms associated with pharyngitis |
US8999372B2 (en) * | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US20060035008A1 (en) * | 2002-11-14 | 2006-02-16 | Givaudan Sa | Edible film containing food acid |
US9561182B2 (en) * | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US20040191302A1 (en) * | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US20040111275A1 (en) * | 2002-11-15 | 2004-06-10 | Kroll David B. | Methods for marketing and generating revenue from edible thin films |
US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
CA2504814A1 (en) | 2002-12-02 | 2004-06-17 | Kyukyu Pharmaceutical Co., Ltd. | Process for producing edible orally administered agent of laminate film form and compression bonding apparatus |
DK1568277T3 (en) * | 2002-12-04 | 2010-07-19 | Mitsui Chemicals Agro Inc | Method of preventing mycotoxin contamination of wheat |
DE10256775A1 (en) * | 2002-12-05 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Preparation of film forming composition for transmucosal delivery of nicotine used for treating tobacco addiction, includes converting nicotine free base to its salt with acid and/or incorporation of nicotine as salt |
CA2508145A1 (en) * | 2002-12-06 | 2004-06-24 | Monosolrx Llc | Thin film delivery systems for volatile decongestants |
US20040115137A1 (en) * | 2002-12-17 | 2004-06-17 | Verrall Andrew P. | Water-soluble film for oral administration |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US6669929B1 (en) * | 2002-12-30 | 2003-12-30 | Colgate Palmolive Company | Dentifrice containing functional film flakes |
ATE553746T1 (en) * | 2003-01-30 | 2012-05-15 | Monosolrx Llc | METHOD FOR PRODUCING A THIN FILM CONTAINING THERMOLABILITY ACTIVE INGREDIENTS |
US20040156794A1 (en) * | 2003-02-11 | 2004-08-12 | Barkalow David G. | Bioerodible and bioadhesive confectionery products and methods of making same |
US7041311B2 (en) * | 2003-02-28 | 2006-05-09 | International Flavors & Fragrances Inc. | Preparation for saliva flow |
US20040228892A1 (en) * | 2003-02-28 | 2004-11-18 | Berry Craig J. | Delivery system for cosmetic and skincare products |
WO2004087089A2 (en) * | 2003-03-26 | 2004-10-14 | The Procter & Gamble Company | Rapidly dissolving edible film compositions with improved film strength and stability |
EP1605905A1 (en) * | 2003-03-26 | 2005-12-21 | The Procter & Gamble Company | Rapidly dissolving edible film compositions with cellulose film forming polymers |
US20040202698A1 (en) * | 2003-04-02 | 2004-10-14 | The Procter & Gamble Company | Drug delivery systems comprising an encapsulated active ingredient |
EP1620059A2 (en) * | 2003-04-14 | 2006-02-01 | Fmc Corporation | Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
US20050013847A1 (en) * | 2003-04-14 | 2005-01-20 | Fmc Corporation | Delivery systems of homogeneous, thermoreversible alginate films |
US20050019294A1 (en) * | 2003-04-14 | 2005-01-27 | Fmc Corporation | Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
AU2004319243B2 (en) * | 2003-05-28 | 2010-06-03 | Aquestive Therapeutics, Inc. | Polyethylene oxide-based films and drug delivery systems made therefrom |
GB0312425D0 (en) * | 2003-05-30 | 2003-07-09 | Boots Co Plc | Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith |
US20040241294A1 (en) * | 2003-05-31 | 2004-12-02 | Barabolak Roman M. | Edible films including aspartame and methods of making same |
US8703209B2 (en) * | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
ES2291908T5 (en) * | 2003-06-23 | 2011-05-25 | Colgate-Palmolive Company | STABLE DENTROPHIC COMPOSITIONS. |
US20040258630A1 (en) | 2003-06-23 | 2004-12-23 | Boyd Thomas J. | Antiplaque breath freshening consumable film |
US8287843B2 (en) * | 2003-06-23 | 2012-10-16 | Colgate-Palmolive Company | Antiplaque oral care compositions |
DE10328942A1 (en) * | 2003-06-27 | 2005-01-27 | Lts Lohmann Therapie-Systeme Ag | Transmucosal dosage forms with reduced mucous membrane irritation |
ES2654062T3 (en) * | 2003-07-24 | 2018-02-12 | Glaxosmithkline Llc | Oral Dissolution Films |
US7666396B2 (en) * | 2003-09-11 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Single-use moisturizing product |
US20050080039A1 (en) * | 2003-10-14 | 2005-04-14 | Cp Kelco, U.S., Inc. | Pectin films prepared from gamma irradiated pectin |
CA2543324C (en) | 2003-10-24 | 2011-02-01 | Adhesives Research, Inc. | Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
AU2004289248B2 (en) | 2003-11-07 | 2012-05-03 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US7182964B2 (en) * | 2003-11-13 | 2007-02-27 | Dbc, Llc | Dissolving thin film xanthone supplement |
DE10354894A1 (en) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Oral formulations of deoxypeganine and their applications |
DE10358747A1 (en) * | 2003-12-12 | 2005-07-07 | Lts Lohmann Therapie-Systeme Ag | Dosage form based on crosslinked hydrophilic polymers |
RU2006125452A (en) * | 2003-12-16 | 2008-01-27 | Колгейт-Палмолив Компани (US) | COMPOSITIONS AND METHODS FOR CARE OF THE ORAL CAVITY AND BODY |
DE102004002951A1 (en) * | 2004-01-21 | 2005-08-11 | Wella Ag | Process for producing hair-setting products in film form |
FR2865130B1 (en) * | 2004-01-21 | 2007-10-05 | Oreal | ANHYDROUS FILM FOR MAKE-UP OR CARE OF LIPS. |
WO2005074894A1 (en) | 2004-01-30 | 2005-08-18 | Corium International | Rapidly dissolving film for delivery of an active agent |
US20050186256A1 (en) * | 2004-02-20 | 2005-08-25 | Dihel Deborah L. | Dissolvable film comprising an active ingredient and method of manufacture |
WO2005092271A1 (en) * | 2004-03-03 | 2005-10-06 | Warner-Lambert Company Llc | Film compositions |
US20080003248A1 (en) * | 2004-03-03 | 2008-01-03 | Constantine Georgiades | Whitening products |
US20070269519A1 (en) * | 2004-03-03 | 2007-11-22 | Constantine Georgiades | Whitening products |
US20050196354A1 (en) * | 2004-03-03 | 2005-09-08 | Andre Soshinsky | Film compositions |
US20050196355A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
US20050196348A1 (en) * | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Stabilized peroxide compositions |
US20070190125A1 (en) * | 2004-03-03 | 2007-08-16 | Constantine Georgiades | Positioning feature for aiding use of film or strip product |
US20050208108A1 (en) * | 2004-03-19 | 2005-09-22 | Jannusch Leonard C | Thermoplastic films and methods for making |
US7850987B2 (en) * | 2004-04-08 | 2010-12-14 | Micronutrient, Llc | Nutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US7785619B2 (en) * | 2004-04-08 | 2010-08-31 | Micro Nutrient, Llc | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
US20050226906A1 (en) * | 2004-04-08 | 2005-10-13 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
NZ551336A (en) * | 2004-04-22 | 2010-04-30 | Acucort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
US20050249782A1 (en) * | 2004-05-04 | 2005-11-10 | Victor Perry | Drug delivery device |
US7399482B1 (en) | 2004-05-07 | 2008-07-15 | Christine Horner Biernacki | Thin film medication device and kit |
US7972589B2 (en) * | 2004-05-17 | 2011-07-05 | Akzo Nobel N.V. | Hair fixative film |
WO2005120455A1 (en) * | 2004-06-12 | 2005-12-22 | Passion For Life Healthcare Limited | Soluble strip for oral or topical administration |
KR100874802B1 (en) * | 2004-06-22 | 2008-12-19 | 이-엘 매니지먼트 코포레이션 | Soluble film composition |
US20060024425A1 (en) | 2004-07-30 | 2006-02-02 | Wm. Wrigley Jr. Company | Edible film compositions |
MX2007001512A (en) | 2004-08-05 | 2007-04-20 | Corium Int Inc | Adhesive composition. |
DE102005003387A1 (en) * | 2004-09-01 | 2006-03-02 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios |
DK1791791T3 (en) * | 2004-09-27 | 2019-08-26 | Special Water Patents B V | Methods and compositions for treating water |
WO2007099398A2 (en) | 2005-09-27 | 2007-09-07 | Naturalite Benelux B.V. | Methods and compositions for treatment of skin |
KR101388955B1 (en) * | 2004-09-30 | 2014-04-24 | 더 허쉬 컴퍼니 | Sealed, edible film strip packets and methods of making and using them |
JP4898113B2 (en) * | 2004-12-02 | 2012-03-14 | リンテック株式会社 | Oral administration |
AU2006206252B2 (en) | 2005-01-19 | 2009-11-05 | Neurohealing Pharmaceuticals, Inc. | Methods and compositions for decreasing saliva production |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US8299025B2 (en) | 2005-02-03 | 2012-10-30 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
DE102005007859A1 (en) * | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Procedures for a combination drug treatment, as well as suitable drug combinations |
US7992575B2 (en) * | 2005-02-28 | 2011-08-09 | U.S. Smokeless Tobacco Company | Use of chlorate, sulfur or ozone to reduce tobacco specific nitrosamines |
US20060216318A1 (en) * | 2005-03-10 | 2006-09-28 | Gopa Majmudar | Compositions comprising entrained water and agents entrained in water-sensitive matrices |
DE102005015128B4 (en) * | 2005-03-31 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Wafers containing steroid hormones |
WO2006107390A2 (en) | 2005-04-04 | 2006-10-12 | Kronos Advanced Technologies, Inc. | An electrostatic fluid accelerator for and method of controlling a fluid flow |
US20060228307A1 (en) * | 2005-04-08 | 2006-10-12 | Cao Group, Inc. | Structures and methods for delivering topical compositions |
KR20080007449A (en) * | 2005-05-03 | 2008-01-21 | 이노젠, 인크. | Edible film for transmucosal delivery of nutritional supplements |
US20060260366A1 (en) * | 2005-05-18 | 2006-11-23 | I+Dcreative, Llc | Laundry appliance for washing small quantities of clothing |
JP5215175B2 (en) * | 2005-05-25 | 2013-06-19 | ユーエス スモークレス タバコ カンパニー リミテッド ライアビリティ カンパニー | Tobacco composition |
WO2006127879A1 (en) * | 2005-05-26 | 2006-11-30 | Duramed Pharmaceuticals, Inc. | Flexible solid dosage forms and methods of making and using the same |
US9023382B2 (en) * | 2005-06-08 | 2015-05-05 | Basf Corporation | Medicament carrier composition and method of forming a film therefrom |
DE102005033543A1 (en) * | 2005-07-14 | 2007-01-18 | Grünenthal GmbH | A fragrance-containing transdermal therapeutic system |
DE102005033943A1 (en) * | 2005-07-20 | 2007-02-22 | Hexal Ag | Non-spitting, oral, fast-disintegrating film for a neuroleptic |
EP1909573A4 (en) * | 2005-07-21 | 2010-09-22 | Neurohealing Pharmaceuticals I | Rapid onset and short term modafinil compositions and methods of use thereof |
BRPI0614197B8 (en) * | 2005-08-02 | 2021-05-25 | Drossapharm Ag | pharmaceutically effective composition in a dosage form for peroral administration containing at least one of the active ingredients indomethacin and acemetacin, forms of administration, and use of the composition |
US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
US20070104769A1 (en) * | 2005-11-04 | 2007-05-10 | Lifescience Plus, Inc. | Bioabsorbable hemostatic gauze |
WO2007056066A2 (en) | 2005-11-04 | 2007-05-18 | Lifescience Plus, Inc. | Bioabsorbable hemostatic gauze |
US7544377B2 (en) * | 2005-12-02 | 2009-06-09 | Gic Innovations Company | Chewable compositions with fast release magnolia bark extract |
CN101321513A (en) * | 2005-12-02 | 2008-12-10 | Gic创新公司 | Vehicles for oral care with magnolia bark extract |
DK1954301T3 (en) * | 2005-12-02 | 2013-08-05 | Gic Innovations Company | CONFECTURE COMPOSITIONS WITH MAGNOLIA BARK EXTRACT |
EP1971312A1 (en) * | 2005-12-06 | 2008-09-24 | MonoSol Rx LLC | Topical film compositions for delivery of actives |
US20070148213A1 (en) * | 2005-12-22 | 2007-06-28 | Sayed Ibrahim | Film containing compositions |
SE530184C2 (en) * | 2005-12-23 | 2008-03-18 | Kjell Stenberg | Bioadhesive pharmaceutical film composition containing low viscous alginates |
CN101346135A (en) * | 2005-12-27 | 2009-01-14 | 莫诺索尔克斯有限公司 | PH modulated films for delivery of actives |
WO2007078874A2 (en) * | 2005-12-30 | 2007-07-12 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
WO2007084587A2 (en) * | 2006-01-20 | 2007-07-26 | Monosol Rx, Llc | Film lined pouch and method of manufacturing this pouch |
JP4668798B2 (en) * | 2006-01-25 | 2011-04-13 | 株式会社ツキオカ | Water-soluble cleaning film |
AU2007214474B2 (en) * | 2006-02-17 | 2011-01-20 | Novartis Ag | Disintegrable oral films |
US8986735B2 (en) * | 2006-03-16 | 2015-03-24 | Novartis Ag | Solid dosage form containing a taste masked active agent |
SI2007362T1 (en) | 2006-04-04 | 2018-12-31 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
US20070231387A1 (en) * | 2006-04-04 | 2007-10-04 | Luigi Levi | Film-coated solid dosage forms |
WO2007127810A2 (en) * | 2006-04-25 | 2007-11-08 | Kronos Advanced Technologies, Inc. | Electrostatic loudspeaker and method of acoustic waves generation |
IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
KR101106510B1 (en) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | Two-piece, internal-channel osmotic delivery system flow modulator |
US20080152761A1 (en) * | 2006-12-20 | 2008-06-26 | Shiji Shen | Packaging of Food Products with Pullulan Films |
US8642016B2 (en) * | 2006-07-21 | 2014-02-04 | Jsrnti, Llc | Medicinal delivery system, and related methods |
HUE027395T2 (en) | 2006-07-21 | 2016-10-28 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with enhanced uptake |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
DK2056811T3 (en) * | 2006-08-14 | 2018-05-22 | Neurohealing Pharmaceuticals Inc | Modafinil-based treatment for premature ejaculation |
AU2006347731B2 (en) * | 2006-08-31 | 2012-09-13 | Kimberly-Clark Worldwide, Inc. | Highly breathable biodegradable films |
AU2007297697A1 (en) * | 2006-09-20 | 2008-03-27 | Monosol Rx Llc | Edible water-soluble film containing a foam reducing flavoring agent |
CA2664615A1 (en) * | 2006-09-29 | 2008-04-10 | Monosol Rx, Llc | Film embedded packaging and method of making same |
US20080131467A1 (en) * | 2006-11-30 | 2008-06-05 | Dennis Nelson | Film-coated solid dosage form |
WO2008089151A2 (en) * | 2007-01-12 | 2008-07-24 | Monosol Rx, Llc | High dose film compositions and methods of preparation |
EP2112923A1 (en) | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
CA2678500A1 (en) * | 2007-02-15 | 2008-08-21 | Derma-Young Ltd. | Compositions and methods for enhancing transmucosal delivery |
US20080220029A1 (en) * | 2007-03-05 | 2008-09-11 | Charlene Ng | Fast-dissolving/disintegrating film preparation having high proportion of active |
CN101621990B (en) * | 2007-03-07 | 2012-11-21 | 诺瓦提斯公司 | Orally administrable films |
US20090011115A1 (en) * | 2007-03-13 | 2009-01-08 | Foss Carter D | Edible Pullulan Films Containing Flavoring |
US20090087468A1 (en) * | 2007-03-28 | 2009-04-02 | Serena Stephenson | Semi-Rigid Gel Article For Disinfecting A Surface |
US20080274252A1 (en) * | 2007-04-12 | 2008-11-06 | Hoffman Andrew J | Pullulan film containing sweetener |
US20080292683A1 (en) * | 2007-05-24 | 2008-11-27 | Monosolrx, Llc. | Film shreds and delivery system incorporating same |
US8765155B2 (en) * | 2007-08-30 | 2014-07-01 | Colgate-Palmolive Company | Oral care strip or tape and methods of use and manufacture thereof |
US9271524B1 (en) | 2007-09-07 | 2016-03-01 | U.S. Smokeless Tobacco Company | Tobacco having reduced tobacco specific nitrosamine content |
US20090098192A1 (en) * | 2007-10-11 | 2009-04-16 | Fuisz Richard C | Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same |
US9125434B2 (en) | 2007-10-11 | 2015-09-08 | Philip Morris Products S.A. | Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet |
MY185299A (en) | 2007-10-11 | 2021-04-30 | Philip Morris Products Sa | Smokeless tobacco product |
WO2009058557A2 (en) | 2007-10-12 | 2009-05-07 | Euthanix Corp. | Method and apparatus for euthanizing animals |
US8298583B2 (en) | 2007-10-19 | 2012-10-30 | Monosol Rx, Llc | Film delivery system for tetrahydrolipstatin |
US20090142452A1 (en) * | 2007-11-19 | 2009-06-04 | Michael David Campbell | Dissolvable Orally Consumable Flavored Sensual Enhancement Films |
US20090253754A1 (en) * | 2007-12-04 | 2009-10-08 | Francesca Selmin | Fast dissolving films and coatings for controlled release of flavors, active pharmaceutical ingredients, food substances, and nicotine |
US8227658B2 (en) | 2007-12-14 | 2012-07-24 | Kimberly-Clark Worldwide, Inc | Film formed from a blend of biodegradable aliphatic-aromatic copolyesters |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
CA2714340A1 (en) * | 2008-02-13 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Estradiol-containing drug delivery system |
NZ587309A (en) * | 2008-02-13 | 2012-09-28 | Bayer Schering Pharma Ag | Wafer film systems for for the delivery of estrogen or progestin |
US7998888B2 (en) * | 2008-03-28 | 2011-08-16 | Kimberly-Clark Worldwide, Inc. | Thermoplastic starch for use in melt-extruded substrates |
US9265779B2 (en) | 2008-05-13 | 2016-02-23 | Lts Lohmann Therapie-Systeme Ag | Method of using a film-shaped preparation comprising oily substances for oral administration |
DE102008023345B4 (en) | 2008-05-13 | 2014-12-04 | Lts Lohmann Therapie-Systeme Ag | Film-like preparation with oily substances for oral administration |
US8338508B2 (en) * | 2008-05-14 | 2012-12-25 | Kimberly-Clark Worldwide, Inc. | Water-sensitive film containing an olefinic elastomer |
US8147965B2 (en) * | 2008-05-14 | 2012-04-03 | Kimberly-Clark Worldwide, Inc. | Water-sensitive film containing thermoplastic polyurethane |
ES2525123T3 (en) | 2008-06-04 | 2014-12-17 | Colgate-Palmolive Company | Implementation for oral care with cavitation system |
CA2728912C (en) * | 2008-06-23 | 2018-04-10 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
US8759279B2 (en) * | 2008-06-30 | 2014-06-24 | Kimberly-Clark Worldwide, Inc. | Fragranced biodegradable film |
US8927617B2 (en) | 2008-06-30 | 2015-01-06 | Kimberly-Clark Worldwide, Inc. | Fragranced water-sensitive film |
US8188185B2 (en) * | 2008-06-30 | 2012-05-29 | Kimberly-Clark Worldwide, Inc. | Biodegradable packaging film |
JP2011526888A (en) * | 2008-07-01 | 2011-10-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Oral fast-dissolving thin films for targeted delivery of therapeutic agents |
FR2933959B1 (en) * | 2008-07-16 | 2010-09-10 | Roquette Freres | PROCESS FOR PRODUCING FILMS DIRECTLY IN ALVEOL |
US20100040727A1 (en) * | 2008-08-18 | 2010-02-18 | Monosol Rx, Llc | Method for Improving Uniformity of Content in Edible Film Manufacturing |
US8282954B2 (en) * | 2008-12-15 | 2012-10-09 | Monosol Rx, Llc | Method for manufacturing edible film |
US8283006B2 (en) * | 2008-12-18 | 2012-10-09 | Kimberly-Clark Worldwide, Inc. | Injection molding material containing starch and plant protein |
US8329601B2 (en) | 2008-12-18 | 2012-12-11 | Kimberly-Clark Worldwide, Inc. | Biodegradable and renewable film |
EP2387394B1 (en) | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
US20100183717A1 (en) | 2009-01-16 | 2010-07-22 | Kristin Arnold | Controlled-release formulations |
US9492505B2 (en) * | 2009-01-21 | 2016-11-15 | University Of Florida Research Foundation, Inc. | Satiation peptide administration |
WO2010086989A1 (en) * | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | Intraoral film-shaped base and preparation |
JP5674480B2 (en) * | 2009-01-29 | 2015-02-25 | 日東電工株式会社 | Intraoral film-form base and preparation |
EA021886B1 (en) | 2009-03-04 | 2015-09-30 | Редженера Фарма Лтд. | Isolated fraction of mastic gum |
EA021833B1 (en) | 2009-03-04 | 2015-09-30 | Редженера Фарма Лтд. | Compositions of polymeric myrcene |
US20100256215A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Menthol-Melatonin Dissolving Film |
US20100256197A1 (en) * | 2009-04-02 | 2010-10-07 | Silver Eagle Labs Nv, Llc | Nicotine Dissolving Film With Or Without Menthol |
US20100285130A1 (en) * | 2009-05-06 | 2010-11-11 | Monosol Rx, Llc | Coating of complexed actives in film formulations |
US20100297232A1 (en) * | 2009-05-19 | 2010-11-25 | Monosol Rx, Llc | Ondansetron film compositions |
TWI442937B (en) | 2009-05-26 | 2014-07-01 | Colgate Palmolive Co | Higher loading zinc-containing films |
TWI396554B (en) * | 2009-05-26 | 2013-05-21 | Colgate Palmolive Co | Oral care formulations that enhance amount of soluble zinc |
MX339923B (en) | 2009-05-26 | 2016-06-16 | Colgate-Palmolive Company * | Dentifrice composition. |
ES2554626T3 (en) | 2009-06-12 | 2015-12-22 | Cynapsus Therapeutics Inc. | Sublingual apomorphine |
WO2011012848A1 (en) | 2009-07-27 | 2011-02-03 | Suresensors Ltd | Improvements relating to sensor devices |
WO2011014401A2 (en) * | 2009-07-30 | 2011-02-03 | The Procter & Gamble Company | Oral care articles and methods |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
HUE035862T2 (en) | 2009-09-28 | 2018-05-28 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
CA2779025A1 (en) | 2009-10-28 | 2011-05-05 | Regenera Pharma Ltd. | Therapeutic uses of oligomeric and polymeric monoterpenes |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
US9408798B2 (en) * | 2009-12-04 | 2016-08-09 | Colgate-Palmolive Company | Dissolvable films containing high concentrations of nonionic surfactants such as polysorbates to enhance high solid loadings |
US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
US20110142942A1 (en) * | 2009-12-10 | 2011-06-16 | Monosol Rx, Llc | USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS |
PT2519225E (en) | 2009-12-30 | 2015-07-27 | Novartis Ag | Melt extruded nicotine thin strips |
EP2519224A1 (en) | 2009-12-30 | 2012-11-07 | Novartis AG | Melt extruded thin strips containing coated pharmaceutical actives |
TWI458497B (en) | 2010-01-13 | 2014-11-01 | Colgate Palmolive Co | Stabilization of zinc oxide film in oral compositions |
TWI435733B (en) | 2010-01-29 | 2014-05-01 | Colgate Palmolive Co | Oral care formulations for malodor control |
JP5751868B2 (en) * | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | Film-form preparation and method for producing the same |
US20110276522A1 (en) * | 2010-03-31 | 2011-11-10 | Kehoe Gary S | Standardization and reconstitution of phytochemicals for medical dispensation |
US20110263606A1 (en) * | 2010-04-26 | 2011-10-27 | Horst Zerbe | Solid oral dosage forms comprising tadalafil |
US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
US20110269844A1 (en) * | 2010-05-03 | 2011-11-03 | Innoteq, Inc. | Thin film with propofol active ingredient |
US20110269841A1 (en) * | 2010-05-03 | 2011-11-03 | Innoteq, Inc. | Thin film with methadone active ingredient |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
WO2011156711A1 (en) | 2010-06-10 | 2011-12-15 | Schobel Alexander M | Nanoparticle film delivery systems |
EP2588200B1 (en) | 2010-06-30 | 2018-02-28 | Colgate-Palmolive Company | Multilayer films for delivery of flavor |
JP5876052B2 (en) | 2010-09-07 | 2016-03-02 | レジネラ ファーマ リミテッド | Composition comprising an acidic extract of mastic gum |
DE102010048408A1 (en) | 2010-10-15 | 2012-04-19 | Lts Lohmann Therapie-Systeme Ag | Laminate with improved water retention behavior |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
US10238684B2 (en) | 2010-11-18 | 2019-03-26 | Foundational Biosystems, Llc | Micro- and nano-quantity sleep enhancing nutrient composition and method of enhancing central nervous system protein clearance using same |
MY163370A (en) | 2010-12-07 | 2017-09-15 | Colgate Palmolive Co | Oral and personal care compositions |
ES2791715T3 (en) | 2010-12-16 | 2020-11-05 | Sunovion Pharmaceuticals Inc | Sublingual Movies |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012149326A1 (en) | 2011-04-29 | 2012-11-01 | Massachusetts Institute Of Technology | Layer processing for pharmaceuticals |
US8241661B1 (en) * | 2011-06-24 | 2012-08-14 | Fuisz Richard C | Biocompatible film with variable cross-sectional properties |
KR101303479B1 (en) * | 2011-07-28 | 2013-09-06 | (주)씨엘팜 | Composition for edible film and pharmaceutical preparation for edible film containing drugs |
ES2660116T3 (en) | 2011-08-18 | 2018-03-20 | Biodelivery Sciences International, Inc. | Mucoadhesive devices resistant to improper use for buprenorphine administration |
US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
WO2013114153A2 (en) | 2011-12-14 | 2013-08-08 | Lts Lohmann Therapie-Systeme Ag | Wafer and capsule formulations with enhanced dissolution rates for fenofibrate |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
JP5841433B2 (en) | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | Intraoral film-form base and preparation |
US10806703B2 (en) | 2012-01-20 | 2020-10-20 | Lts Lohmann Therapie-System Ag | Transmucosal administration system for a pharmaceutical drug |
US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
FR2990349B1 (en) | 2012-05-11 | 2014-08-08 | Pf Medicament | FAST DISINTEGRATING MONOLAYER FILM AND ITS USE IN ORAL HYGIENE |
JP6050031B2 (en) * | 2012-06-01 | 2016-12-21 | 森下仁丹株式会社 | Film formulation |
RU2510558C1 (en) * | 2012-07-19 | 2014-03-27 | Александр Викторович Атаманов | Wireless charging system for low-power consumers of electrical energy |
CA2878680C (en) | 2012-07-23 | 2019-09-17 | Crayola, Llc | Dissolvable films and methods of using the same |
US10829621B2 (en) | 2013-01-11 | 2020-11-10 | Monosol, Llc | Edible water-soluble film |
WO2014145699A1 (en) | 2013-03-15 | 2014-09-18 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
BR112015021417A2 (en) | 2013-03-15 | 2017-07-18 | Smith & Nephew Inc | dissolvable gel forming film for the delivery of active agents |
US9303918B2 (en) | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
US20140275194A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Films and drug delivery systems for rizatriptan |
US9278050B2 (en) | 2013-04-01 | 2016-03-08 | Trevor Anderson | Dissolvable medication administration bag and method of using the same |
ES2706481T3 (en) | 2013-07-31 | 2019-03-29 | Intelgenx Corp | Dosage form in oral film, instantly wettable without surfactant or polyalcohol |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US20150182992A1 (en) | 2013-12-31 | 2015-07-02 | Johnson & Johnson Consumer Companies, Inc. | Process for forming a multilayered shaped film product |
BR112016015347B8 (en) | 2013-12-31 | 2022-07-19 | Johnson & Johnson Consumer Inc | PROCESS FOR FORMING A FILM PRODUCT WITH A MULTI-LAYER FORMAT, A FILM PRODUCT WITH A MULTI-LAYER FORMAT AND APPARATUS FOR FORMING A FILM PRODUCT WITH A MULTI-LAYER FORMAT |
CA2935191C (en) | 2013-12-31 | 2021-11-09 | Johnson & Johnson Consumer Inc. | Process for forming a shaped film product |
DK3125893T3 (en) | 2014-04-04 | 2023-11-20 | Intra Cellular Therapies Inc | DEUTERATED HETEROCYCLE-FUSIONED GAMMA CARBOLINES AS 5-HT2A RECEPTOR ANTAGONISTS |
WO2015179461A1 (en) | 2014-05-20 | 2015-11-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CA2969466A1 (en) * | 2014-12-09 | 2016-06-16 | Monosolrx Llc | Linear polysaccharide based film products |
KR101695071B1 (en) | 2014-12-26 | 2017-01-11 | 연세대학교 산학협력단 | Pharmaceutical composition of liquid state drug dispersed film form |
JP7211706B2 (en) | 2015-04-21 | 2023-01-24 | サノヴィオン ファーマシュティカルズ インコーポレーテッド | Method for treating Parkinson's disease by administering apomorphine to oral mucosa |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
US10532046B2 (en) | 2015-12-03 | 2020-01-14 | Niconovum Usa, Inc. | Multi-phase delivery compositions and products incorporating such compositions |
US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
CA3048820A1 (en) * | 2015-12-30 | 2017-07-06 | Next Generation Labs, LLC | Nicotine replacement therapy products comprising synthetic nicotine |
WO2017132408A1 (en) | 2016-01-26 | 2017-08-03 | Intra-Cellular Therapies, Inc. | Organic compounds |
PT3407889T (en) | 2016-03-25 | 2021-07-14 | Intra Cellular Therapies Inc | Organic compounds |
US11311633B2 (en) | 2016-04-16 | 2022-04-26 | University Of Florida Research Foundation, Incorporated | Satiation peptides for weight loss and altered taste sensitivity |
CN109310646A (en) | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Enhance the adrenaline composition of delivering |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
BR112018073511A2 (en) | 2016-05-16 | 2019-03-26 | Intarcia Therapeutics, Inc. | glucagon receptor selective polypeptides and methods of use |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3534974A4 (en) * | 2016-11-02 | 2020-07-01 | Board of Regents, The University of Texas System | Dissolvable films and methods of their use |
WO2018126143A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN110225762A (en) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent |
IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
US9901545B1 (en) | 2017-04-13 | 2018-02-27 | Richard C. Fuisz | Method and composition for making an oral soluble film, containing at least one active agent |
US10238600B2 (en) | 2017-04-13 | 2019-03-26 | Richard C. Fuisz | Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent |
EP3644745A4 (en) | 2017-06-27 | 2021-04-21 | The Coca-Cola Company | Oral sweetener compositions and methods |
US11911492B2 (en) | 2018-05-14 | 2024-02-27 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
EP3793691A1 (en) | 2018-05-14 | 2021-03-24 | The Procter & Gamble Company | Unit-dose oral care compositions |
WO2019239356A1 (en) | 2018-06-15 | 2019-12-19 | R. J. Reynolds Tobacco Company | Purification of nicotine |
GB2574878A (en) * | 2018-06-22 | 2019-12-25 | Biofilm Ltd | Oral compositions and mucoadhesive thin films formed therefrom |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
WO2020047407A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
US10813889B2 (en) | 2018-09-04 | 2020-10-27 | Babak Ghalili | Cannabinoid and menthol compositions and methods |
US11235013B2 (en) | 2018-09-04 | 2022-02-01 | Babak Ghalili | Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods |
CN113271937A (en) * | 2018-10-18 | 2021-08-17 | 艾维奥尔股份有限公司 | Method and apparatus for treating pruritus associated with chronic kidney disease |
JP7388075B2 (en) * | 2019-02-18 | 2023-11-29 | 富士フイルムビジネスイノベーション株式会社 | modeling equipment |
EP3958823A1 (en) | 2019-04-25 | 2022-03-02 | The Procter & Gamble Company | Oral care compositions for active agent delivery |
CA3136736A1 (en) | 2019-04-25 | 2020-10-29 | The Procter & Gamble Company | Systems and methods for delivering active agents |
CA3136739C (en) | 2019-04-25 | 2024-03-19 | The Procter & Gamble Company | Rinseable multi-phase compositions |
EP3958824A1 (en) | 2019-04-25 | 2022-03-02 | The Procter & Gamble Company | Oral care compositions for active agent delivery |
WO2021168684A1 (en) | 2020-02-26 | 2021-09-02 | The Procter & Gamble Company | Oral care compositions for gum health |
WO2021168696A1 (en) | 2020-02-26 | 2021-09-02 | The Procter & Gamble Company | Oral care compositions for gum health |
WO2021177937A1 (en) * | 2020-03-02 | 2021-09-10 | Babak Ghalili | Cannabinoid and menthol compositions and methods |
WO2021177941A1 (en) * | 2020-03-03 | 2021-09-10 | Babak Ghalili | Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods |
DE102020112143B4 (en) | 2020-05-05 | 2022-03-17 | Lts Lohmann Therapie-Systeme Ag | Nicotine - Corona |
US11173114B1 (en) | 2020-07-10 | 2021-11-16 | Nova Thin Film Pharmaceuticals Llc | Method and system for manufacturing and oral soluble films and oral soluble films made by thereby |
WO2022178279A1 (en) * | 2021-02-19 | 2022-08-25 | Nova Thin Film Pharmaceuticals Llc | Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof |
CA3229228A1 (en) | 2021-08-23 | 2023-03-02 | The Procter & Gamble Company | Oral care compositions for gum health |
CN117835952A (en) | 2021-08-23 | 2024-04-05 | 宝洁公司 | Oral care composition for gingival health |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4332789A (en) * | 1975-12-15 | 1982-06-01 | Hoffmann-La Roche Inc. | Pharmaceutical unit dosage forms |
US4486436A (en) * | 1982-07-22 | 1984-12-04 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US4517173A (en) * | 1980-09-26 | 1985-05-14 | Nippon Soda Co. Ltd. | Mucous membrane-adhering film preparation and process for its preparation |
US5032387A (en) * | 1986-11-06 | 1991-07-16 | Princeton Pharmaceutical Inc. | Dental and oral hygiene preparations |
US5780045A (en) * | 1992-05-18 | 1998-07-14 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931824A (en) * | 1973-09-10 | 1976-01-13 | Celanese Corporation | Smoking materials |
US4007290A (en) * | 1974-01-09 | 1977-02-08 | General Foods Corporation | Caffeine antagonim |
DE2449865B2 (en) * | 1974-10-17 | 1981-06-19 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Film-shaped medicinal product |
DE2432925C3 (en) * | 1974-07-05 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | Film-shaped medicinal products |
US4136162A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
US4136145A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
IN142428B (en) * | 1974-07-05 | 1977-07-09 | Schering Ag | |
US4082841A (en) * | 1975-10-10 | 1978-04-04 | Lever Brothers Company | Dentifrice |
ZA767136B (en) * | 1975-12-15 | 1977-10-26 | Hoffmann La Roche | Novel dosage form |
US4029757A (en) * | 1975-12-15 | 1977-06-14 | Hoffmann-La Roche Inc. | Manufacture of pharmaceutical unit dosage forms |
US4029758A (en) * | 1975-12-15 | 1977-06-14 | Hoffmann-La Roche Inc. | Preparation of pharmaceutical unit dosage forms |
US4031200A (en) * | 1975-12-15 | 1977-06-21 | Hoffmann-La Roche Inc. | Manufacture of pharmaceutical unit dosage forms |
US4713239A (en) * | 1979-05-29 | 1987-12-15 | Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr | Antianginal film and method of treating ischemic heart disease |
GB8301659D0 (en) | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
JPS6130516A (en) * | 1984-07-20 | 1986-02-12 | Nichiban Co Ltd | Mucosa adhesive pharmaceutical |
JPS6185315A (en) * | 1984-10-04 | 1986-04-30 | Teikoku Seiyaku Kk | Sheet-like preparation |
US4900556A (en) | 1985-04-26 | 1990-02-13 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
US4772470A (en) * | 1985-04-27 | 1988-09-20 | Nitto Electric Industrial Co., Ltd. | Oral bandage and oral preparations |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US5783207A (en) | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
JPS61280423A (en) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
ATE59289T1 (en) * | 1985-10-09 | 1991-01-15 | Desitin Arzneimittel Gmbh | PROCESS FOR PREPARING A PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL INGREDIENTS, REAGENTS OR OTHER INGREDIENTS. |
US5229164A (en) * | 1985-12-19 | 1993-07-20 | Capsoid Pharma Gmbh | Process for producing individually dosed administration forms |
JPH0729915B2 (en) * | 1986-02-01 | 1995-04-05 | 帝國製薬株式会社 | Sheet-shaped oral patch |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US4713243A (en) * | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
DE3630603A1 (en) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
GB8630273D0 (en) * | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
US4855142A (en) * | 1987-02-27 | 1989-08-08 | Ciba-Geigy Corporation | Pharmaceutical plaster |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4900552A (en) * | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
DE3827561C1 (en) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
JP2656338B2 (en) * | 1989-01-31 | 1997-09-24 | 日東電工株式会社 | Oral mucosa patch preparation |
JPH02258718A (en) * | 1989-03-31 | 1990-10-19 | Nippon Kayaku Co Ltd | Pasty base and pharmaceutical |
US5824334A (en) * | 1989-09-05 | 1998-10-20 | University Of Utah Research Foundation | Tobacco substitute |
US5354551A (en) * | 1989-10-14 | 1994-10-11 | Desitin Arzneimittel Gmbh | Oral and dental hygiene preparation |
DK0452446T3 (en) * | 1989-10-14 | 1994-01-24 | Desitin Arzneimittel Gmbh | Oral and dental care |
US5525351A (en) * | 1989-11-07 | 1996-06-11 | Dam; Anders | Nicotine containing stimulant unit |
JPH03209327A (en) * | 1990-01-11 | 1991-09-12 | Teikoku Seiyaku Kk | Nicotine-containing cataplasm for oral cavity membrane |
GB9009390D0 (en) | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Pharmaceutical compositions |
US5147854A (en) * | 1990-05-22 | 1992-09-15 | Hoffmann-La Roche Inc. | Tgf-b compositions and method |
DE4018247A1 (en) * | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | MANUFACTURING METHOD FOR QUICK-DISINFITTING FILM-SHAPED PHARMACEUTICAL FORMS |
ES2064117T3 (en) * | 1990-07-23 | 1995-01-16 | Alza Corp | ORAL OSMOTIC DEVICE FOR THE SUPPLY OF NICOTINE. |
US5147654A (en) | 1990-07-23 | 1992-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
US5686094A (en) * | 1991-04-01 | 1997-11-11 | Theratech, Inc. | Controlled release formulations for the treatment of xerostomia |
AU8733491A (en) * | 1990-10-25 | 1992-05-26 | Boots Company Plc, The | Mouthwash |
SE9003712L (en) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | GEL-PHARMACEUTICAL LIQUID COMPOSITION AND APPLICATION THEREOF IN PHARMACEUTICAL COMPOSITIONS |
IT1250421B (en) * | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES. |
JPH05236885A (en) | 1991-07-17 | 1993-09-17 | Tazawa Toshihiko | Flavoring and refreshing food formed into film |
JPH0541602A (en) | 1991-08-06 | 1993-02-19 | Fujitsu General Ltd | Primary radiator in common use with circularly polarized wave and linearly polarized wave |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
AU658681B2 (en) * | 1991-10-23 | 1995-04-27 | Block Drug Company Inc., The | Penetration enhancement of topically applied formulations |
US5414005A (en) * | 1993-10-28 | 1995-05-09 | Dynagen, Inc. | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation |
US5346701A (en) * | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
WO1995005416A2 (en) * | 1993-08-19 | 1995-02-23 | Cygnus Therapeutic Systems | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
WO1995018046A1 (en) | 1993-12-28 | 1995-07-06 | Frank Richard D | Pakaging and dispensing device for sterile articles |
EP0743842B1 (en) | 1994-03-07 | 2003-08-13 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
DE69510894T2 (en) | 1994-06-16 | 2000-02-03 | Pharmacia & Upjohn Spa | Process for the production of mucoadhesive starch |
AU2703795A (en) | 1994-06-23 | 1996-01-19 | Procter & Gamble Company, The | Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine |
US6436407B1 (en) * | 1994-08-26 | 2002-08-20 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic adjuvant |
WO1996025910A1 (en) * | 1995-02-23 | 1996-08-29 | Cygnus, Inc. | Water-soluble pressure-sensitive mucoadhesive |
FR2733684B1 (en) * | 1995-05-03 | 1997-05-30 | Cird Galderma | USE OF RETINOIDS IN A COSMETIC COMPOSITION OR FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION |
JP2791317B2 (en) | 1995-12-26 | 1998-08-27 | 株式会社三和化学研究所 | Multilayer film preparation |
FR2742989B1 (en) * | 1995-12-29 | 1998-01-23 | Adir | BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS |
DE19615820A1 (en) * | 1996-04-06 | 1997-10-09 | Holger Specht | Dental care products containing orally absorbable components |
US5955098A (en) | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
US5955096A (en) * | 1996-06-25 | 1999-09-21 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients |
US5853740A (en) * | 1996-08-07 | 1998-12-29 | Abbott Laboratories | Delivery system for pharmaceutical agents encapsulated with oils |
US5871905A (en) * | 1996-09-04 | 1999-02-16 | Epitope, Inc. | Reduction of false positives in oral-fluid based immunoassays |
DE19646392A1 (en) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
JP3460538B2 (en) | 1997-10-08 | 2003-10-27 | 救急薬品工業株式会社 | Fast dissolving film preparation |
DE19837073A1 (en) | 1998-08-17 | 2000-03-23 | Lohmann Therapie Syst Lts | Foil-shaped drug carriers |
US6165512A (en) * | 1998-10-30 | 2000-12-26 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
US6335023B1 (en) * | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
DE19932603A1 (en) | 1999-07-13 | 2001-01-25 | Gruenenthal Gmbh | Multi-layer film containing active substance made of in-situ cross-linked hydrophilic polymers |
DK1204699T3 (en) | 1999-07-22 | 2005-08-15 | Warner Lambert Co | Film compositions of pullulan |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
JP4044709B2 (en) | 1999-11-19 | 2008-02-06 | 信越化学工業株式会社 | Water-based film coating agent and oral solid preparation |
DE10032456A1 (en) | 2000-07-04 | 2002-01-31 | Lohmann Therapie Syst Lts | Rapidly disintegrating dosage form for the release of active substances in the mouth or in the body cavities |
DE10107659B4 (en) | 2001-02-19 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Mucoadhesive disintegratable drug preparation for drug administration in veterinary and human medicine |
US20030068376A1 (en) | 2001-04-20 | 2003-04-10 | Lavipharm Laboratories Inc. | Intraoral delivery of nicotine for smoking cessation |
CN1462194B (en) | 2001-04-24 | 2013-04-24 | 琳得科株式会社 | Oral preparations and supports for oral preparations |
WO2003003957A1 (en) * | 2001-07-06 | 2003-01-16 | Lavipharm Laboratories Inc. | Quick dissolving oral mucosal drug delivery device with moisture barrier coating |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
JP5089840B2 (en) | 2001-09-25 | 2012-12-05 | 救急薬品工業株式会社 | Nicotine-containing film preparation |
DK2332523T4 (en) | 2001-10-12 | 2022-02-21 | Aquestive Therapeutics Inc | Uniform films for rapid-dissolution dosage form containing taste-masking preparations |
-
1996
- 1996-11-11 DE DE19646392A patent/DE19646392A1/en not_active Withdrawn
-
1997
- 1997-08-01 US US08/904,607 patent/US5948430A/en not_active Expired - Lifetime
- 1997-10-21 TW TW092105140A patent/TWI250029B/en not_active IP Right Cessation
- 1997-10-21 TW TW086115552A patent/TW533083B/en not_active IP Right Cessation
- 1997-10-22 SK SK5041-2005A patent/SK285999B6/en not_active IP Right Cessation
- 1997-10-22 DE DE59712993T patent/DE59712993D1/en not_active Expired - Lifetime
- 1997-10-22 EP EP03014213A patent/EP1362584B1/en not_active Expired - Lifetime
- 1997-10-22 PT PT97911237T patent/PT936905E/en unknown
- 1997-10-22 JP JP52208898A patent/JP4063331B2/en not_active Expired - Lifetime
- 1997-10-22 PL PL97333677A patent/PL190376B1/en unknown
- 1997-10-22 SK SK622-99A patent/SK285100B6/en not_active IP Right Cessation
- 1997-10-22 IL IL12981997A patent/IL129819A0/en not_active IP Right Cessation
- 1997-10-22 CZ CZ0164799A patent/CZ297354B6/en not_active IP Right Cessation
- 1997-10-22 EP EP97911237A patent/EP0936905B1/en not_active Expired - Lifetime
- 1997-10-22 KR KR1020057014063A patent/KR100569847B1/en active IP Right Grant
- 1997-10-22 DK DK03014213T patent/DK1362584T3/en active
- 1997-10-22 KR KR1019997004145A patent/KR100604995B1/en not_active IP Right Cessation
- 1997-10-22 DK DK97911237T patent/DK0936905T3/en active
- 1997-10-22 WO PCT/EP1997/005820 patent/WO1998020862A1/en active IP Right Grant
- 1997-10-22 ES ES03014213T patent/ES2322699T3/en not_active Expired - Lifetime
- 1997-10-22 DE DE29724755U patent/DE29724755U1/en not_active Expired - Lifetime
- 1997-10-22 CA CA002265651A patent/CA2265651C/en not_active Expired - Lifetime
- 1997-10-22 HU HU9904207A patent/HU228464B1/en not_active IP Right Cessation
- 1997-10-22 AT AT97911237T patent/ATE247954T1/en active
- 1997-10-22 ES ES97911237T patent/ES2206692T3/en not_active Expired - Lifetime
- 1997-10-22 PT PT03014213T patent/PT1362584E/en unknown
- 1997-10-22 DE DE59710670T patent/DE59710670D1/en not_active Expired - Lifetime
- 1997-10-22 AT AT03014213T patent/ATE422157T1/en active
- 1997-10-22 HU HU0500666A patent/HU230022B1/en unknown
- 1997-10-22 NZ NZ335063A patent/NZ335063A/en not_active IP Right Cessation
- 1997-10-22 SI SI9730590T patent/SI0936905T1/en unknown
- 1997-10-22 TR TR1999/01633T patent/TR199901633T2/en unknown
- 1997-10-22 ID IDW990297A patent/ID22526A/en unknown
- 1997-10-22 AU AU48682/97A patent/AU739698B2/en not_active Ceased
- 1997-11-10 MY MYPI97005325A patent/MY125548A/en unknown
- 1997-11-10 ZA ZA9710093A patent/ZA9710093B/en unknown
-
1999
- 1999-04-06 US US09/287,181 patent/US6177096B1/en not_active Expired - Lifetime
- 1999-04-22 NO NO19991921A patent/NO325073B1/en not_active IP Right Cessation
-
2000
- 2000-02-25 HK HK00101167A patent/HK1035316A1/en not_active IP Right Cessation
- 2000-08-02 US US09/630,562 patent/US6284264B1/en not_active Expired - Lifetime
-
2001
- 2001-08-13 US US09/927,327 patent/US20010046511A1/en not_active Abandoned
-
2002
- 2002-05-14 US US10/143,962 patent/US6709671B2/en not_active Expired - Lifetime
- 2002-06-05 US US10/161,670 patent/US6592887B2/en not_active Expired - Lifetime
-
2004
- 2004-02-05 US US10/771,388 patent/US8865202B2/en not_active Expired - Fee Related
-
2005
- 2005-06-01 JP JP2005161714A patent/JP4817721B2/en not_active Expired - Fee Related
- 2005-07-06 NO NO20053307A patent/NO20053307D0/en not_active Application Discontinuation
- 2005-07-31 IL IL169984A patent/IL169984A/en not_active IP Right Cessation
-
2009
- 2009-09-28 JP JP2009222637A patent/JP2010006832A/en active Pending
-
2011
- 2011-11-09 US US13/292,590 patent/US20120114705A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4332789A (en) * | 1975-12-15 | 1982-06-01 | Hoffmann-La Roche Inc. | Pharmaceutical unit dosage forms |
US4517173A (en) * | 1980-09-26 | 1985-05-14 | Nippon Soda Co. Ltd. | Mucous membrane-adhering film preparation and process for its preparation |
US4486436A (en) * | 1982-07-22 | 1984-12-04 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
US5032387A (en) * | 1986-11-06 | 1991-07-16 | Princeton Pharmaceutical Inc. | Dental and oral hygiene preparations |
US5780045A (en) * | 1992-05-18 | 1998-07-14 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11129799B2 (en) | 2011-04-12 | 2021-09-28 | Aquestive Therapeutics, Inc. | Dual lane coating |
WO2019121660A1 (en) * | 2017-12-20 | 2019-06-27 | Firmenich Sa | Oral care compositions |
US11389383B2 (en) | 2017-12-20 | 2022-07-19 | Firmenich Sa | Oral care compositions |
US11938209B2 (en) | 2017-12-20 | 2024-03-26 | Firmenich Sa | Oral care compositions |
US11723863B2 (en) | 2018-06-22 | 2023-08-15 | Church & Dwight Co., Inc. | Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6177096B1 (en) | Water soluble film for oral administration with instant wettability | |
US9585961B2 (en) | Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents | |
CA3104416A1 (en) | Oral compositions and mucoadhesive thin films formed therefrom | |
JP2000063268A (en) | Oral mucosa adhesion-type controlled release troche and periodontal disease therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |